If you compare the disruptive tech Poet has to a phase 3 pharma drug on the verge of being FDA approved, Mazan's share price evaluation is quite plausible.
--------
Only would make sense if such sale would exclude all the patents that do not relate to the OI. An acquirer should not get those as if they were toss-offs at an estate sale.